SCHEMBL1010703

SCHEMBL1010703

CC(C)(Oc1ccccc1CCCNCC(Oc1ccc(Cl)cc1)c1nc2ccccc2o1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 9/20 0.39
PPARA Q07869 9/20 0.39
PPARD Q03181 4/20 0.39
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.38
THRB P10828 1/20 0.38
ADRB3 P13945 3/20 0.36
PTPN1 P18031 3/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
FABP2 P12104 1/20 0.35
P2RX3 P56373 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1012350 0.95 MAPT (0.39) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL1010640 0.94 PPARG (0.40) PPARGPPARAPPARDMAPTADRB3
SCHEMBL1010312 0.92 MAPT (0.37) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL1012141 0.89 PPARA (0.40) PPARGPPARAPPARDMAPTADRB3
SCHEMBL1010866 0.85 ADRB3 (0.52) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL1010020 0.84 PPARA (0.39) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL1010742 0.84 PPARG (0.51) PPARGPPARAPPARDMAPTADRB3
SCHEMBL1009638 0.83 PPARG (0.50) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL1009671 0.82 PPARA (0.47) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL1010612 0.81 PPARA (0.56) PPARGPPARAPPARDADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1661890-B1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KOWA CO (JP) 2011-01-05 EP disclosed
US-7183295-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2007-02-27 US disclosed
US-7109226-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-09-19 US disclosed
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-08-24 US disclosed
EP-1661890-A1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Kowa Co., Ltd. (JP) 2006-05-31 EP disclosed
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARA, PPARG, PPARD PPARG 2/4885PPARA 1/4885PPARD 3/4885
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARG, PPARA, PPARD PPARG 1/4885PPARA 2/4885PPARD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.